0 results

    Portfolio News

    Sofinnova Crossover

    Sensorion announces the appointment of Laurene Danon as Chief Financial Officer

    Related Deal lead

    Cedric Moreau

    Related Strategy


    Related Company


    MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the appointment of Ms Laurene Danon as Chief Financial Officer.

    Laurene brings to Sensorion more than 15 years of experience in investment banking and international equity capital markets. A graduate of HEC, she began her career in London with the investment bank J.P. Morgan, in corporate finance advisory, before specializing in equity capital markets at J.P. Morgan and later at Jefferies International. Prior to joining Sensorion, she founded the strategic advisory firm Concorde Advisory, where she supported and managed the execution of strategic corporate finance projects for her clients. In total, Laurene has led executions for 70 transactions totaling over $35 billion raised.

    Laurene was well known to the Sensorion team, having advised the company on recent capital increases.

    Laurene Danon, Chief Financial Officer of Sensorion, said: "I am delighted to have the opportunity to join Sensorion at a pivotal moment in its history, marked by a strong acceleration of its programs, particularly in gene therapy. These programs are currently receiving strong support from the medical community, patients and their families, as well as investors. I am determined to work with the whole team at Sensorion to further develop highly innovative therapies for hearing disorders, a significant global unmet medical need."

    Nawal Ouzren, Chief Executive Officer of Sensorion, said: “I am excited to welcome Laurene whose appointment represents excellent news for Sensorion and comes at a time of significant opportunity and growth for Sensorion. She brings a wealth of knowledge that will play a paramount role in supporting advances in Sensorion’s pipeline. With her proven expertise of international capital markets, she will be a great addition to our management’s team and will immensely contribute in Sensorion’s mission to bring potentially life-transformative solutions to people living with hearing disorders.”

    About Sensorion

    Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.

    It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.

    Join our mailing list

    Keep up to date with our latest news.

    Thanks for submitting the form. You are now subscribed to Sofinnova Partners news alerts.An error happened. Please try again later.